143 related articles for article (PubMed ID: 32329185)
1. Stromal deactivation by CSF1: a new feature of the aggressive pancreatic cancer microenvironment.
Vera RE; Fernandez-Zapico ME
EMBO Rep; 2020 May; 21(5):e50468. PubMed ID: 32329185
[TBL] [Abstract][Full Text] [Related]
2. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1.
Steins A; van Mackelenbergh MG; van der Zalm AP; Klaassen R; Serrels B; Goris SG; Kocher HM; Waasdorp C; de Jong JH; Tekin C; Besselink MG; Busch OR; van de Vijver MJ; Verheij J; Dijk F; van Tienhoven G; Wilmink JW; Medema JP; van Laarhoven HW; Bijlsma MF
EMBO Rep; 2020 May; 21(5):e48780. PubMed ID: 32173982
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
4. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
5. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
7. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
[TBL] [Abstract][Full Text] [Related]
8. Missing links - epigenetic regulators of the pancreatic cancer-associated inflammation.
Werba G; Gonda TA
Clin Sci (Lond); 2021 May; 135(10):1289-1293. PubMed ID: 34047338
[TBL] [Abstract][Full Text] [Related]
9. BAG3-positive pancreatic stellate cells promote migration and invasion of pancreatic ductal adenocarcinoma.
Yuan Y; Jiang JY; Wang JM; Sun J; Li C; Liu BQ; Yan J; Meng XN; Wang HQ
J Cell Mol Med; 2019 Aug; 23(8):5006-5016. PubMed ID: 31119886
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of PDAC subtype heterogeneity and therapy response.
Espinet E; Klein L; Puré E; Singh SK
Trends Cancer; 2022 Dec; 8(12):1060-1071. PubMed ID: 36117109
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
13. Stromal SPOCK1 supports invasive pancreatic cancer growth.
Veenstra VL; Damhofer H; Waasdorp C; Steins A; Kocher HM; Medema JP; van Laarhoven HW; Bijlsma MF
Mol Oncol; 2017 Aug; 11(8):1050-1064. PubMed ID: 28486750
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
16. Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype.
Oh K; Yoo YJ; Torre-Healy LA; Rao M; Fassler D; Wang P; Caponegro M; Gao M; Kim J; Sasson A; Georgakis G; Powers S; Moffitt RA
Nat Commun; 2023 Aug; 14(1):5226. PubMed ID: 37633924
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation.
Xiao Q; Zhou D; Rucki AA; Williams J; Zhou J; Mo G; Murphy A; Fujiwara K; Kleponis J; Salman B; Wolfgang CL; Anders RA; Zheng S; Jaffee EM; Zheng L
Cancer Res; 2016 Sep; 76(18):5395-404. PubMed ID: 27496707
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
19. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma.
Hiroshima Y; Kasajima R; Kimura Y; Komura D; Ishikawa S; Ichikawa Y; Bouvet M; Yamamoto N; Oshima T; Morinaga S; Singh SR; Hoffman RM; Endo I; Miyagi Y
Cancer Lett; 2020 Jan; 469():217-227. PubMed ID: 31669204
[TBL] [Abstract][Full Text] [Related]
20. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
